Safety and efficacy of remimazolam compared with propofol in cirrhosis patients undergoing gastroscopic treatment

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045710

Enrollment

Unknown

Registered

2021-04-23

Start date

2021-05-10

Completion date

Unknown

Last updated

2021-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis

Interventions

propofol group:propofol

Remimazolam group:Remimazolam

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with decompensated liver cirrhosis caused by various causes; 2. Patients who agree to receive sedation or anesthesia gastroscopy diagnosis and treatment and sign informed consent.

Exclusion criteria

Exclusion criteria: Those who are allergic to sedatives and anesthetics.

Design outcomes

Primary

Measure	Time frame
recovery time;Extubation time;Blood pressrue;heart rate;	—

Countries

China

Contacts

Public ContactZhao Tonghang

Department of Anesthesiology Liaocheng People's Hospital, Liaocheng, Shandong

lcrmzxj@sina.com+86 13563557789

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026